Skip to main content

Table 2 League table of network meta-analysis for preventing recurrence

From: Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection

TACE

2.53 (0.94,6.81)

0.51 (0.21,1.26)

1.19 (0.50,2.82)

1.45 (0.92,2.27)

0.55 (0.25,1.19)

1.02 (0.50,2.08)

0.84 (0.31,2.27)

0.86 (0.38,1.94)

0.65 (0.25,1.70)

1.55 (0.32,7.40)

1.24 (0.51,3.01)

1.42 (0.45,4.55)

0.63 (0.19,2.06)

0.40 (0.15,1.06)

SOR

0.20 (0.06,0.71)

0.47 (0.15,1.48)

0.57 (0.24,1.38)

0.22 (0.07,0.64)

0.41 (0.14,1.14)

0.33 (0.09,1.16)

0.34 (0.11,1.03)

0.26 (0.08,0.87)

0.61 (0.11,3.48)

0.49 (0.15,1.57)

0.56 (0.14,2.25)

0.25 (0.06,1.02)

1.96 (0.80,4.85)

4.97 (1.41,17.51)

TACE + PVC

2.33 (0.73,7.48)

2.84 (1.15,6.99)

1.08 (0.36,3.23)

2.01 (0.70,5.78)

1.65 (0.46,5.84)

1.69 (0.54,5.22)

1.28 (0.37,4.40)

3.04 (0.53,17.46)

2.43 (0.75,7.93)

2.80 (0.69,11.33)

1.23 (0.30,5.11)

0.84 (0.35,2.01)

2.13 (0.67,6.75)

0.43 (0.13,1.38)

OCT

1.22 (0.58,2.56)

0.46 (0.18,1.22)

0.86 (0.35,2.12)

0.71 (0.22,2.25)

0.72 (0.26,1.98)

0.55 (0.18,1.68)

1.31 (0.25,6.95)

1.04 (0.36,3.04)

1.20 (0.33,4.42)

0.53 (0.14,2.00)

0.69 (0.44,1.09)

1.75 (0.73,4.22)

0.35 (0.14,0.87)

0.82 (0.39,1.73)

NA

0.38 (0.20,0.71)

0.71 (0.41,1.23)

0.58 (0.24,1.41)

0.59 (0.30,1.17)

0.45 (0.19,1.05)

1.07 (0.24,4.79)

0.86 (0.40,1.84)

0.99 (0.34,2.87)

0.43 (0.14,1.31)

1.82 (0.84,3.93)

4.60 (1.56,13.54)

0.93 (0.31,2.77)

2.16 (0.82,5.66)

2.63 (1.41,4.91)

IRT

1.86 (0.82,4.25)

1.53 (0.51,4.52)

1.56 (0.62,3.93)

1.19 (0.42,3.38)

2.82 (0.56,14.27)

2.25 (0.84,6.05)

2.59 (0.75,8.94)

1.14 (0.32,4.05)

0.98 (0.48,1.98)

2.47 (0.87,6.97)

0.50 (0.17,1.43)

1.16 (0.47,2.84)

1.41 (0.81,2.45)

0.54 (0.24,1.23)

IFN

0.82 (0.29,2.33)

0.84 (0.35,2.00)

0.64 (0.23,1.73)

1.51 (0.31,7.45)

1.21 (0.47,3.10)

1.39 (0.42,4.63)

0.61 (0.18,2.10)

1.19 (0.44,3.23)

3.01 (0.86,10.53)

0.61 (0.17,2.15)

1.41 (0.44,4.50)

1.72 (0.71,4.19)

0.66 (0.22,1.94)

1.22 (0.43,3.47)

Huaier

1.02 (0.33,3.14)

0.78 (0.23,2.65)

1.85 (0.32,10.53)

1.48 (0.46,4.77)

1.70 (0.42,6.82)

0.75 (0.18,3.08)

1.17 (0.51,2.64)

2.95 (0.97,8.98)

0.59 (0.19,1.84)

1.38 (0.51,3.78)

1.68 (0.85,3.33)

0.64 (0.25,1.62)

1.19 (0.50,2.86)

0.98 (0.32,3.00)

HAIC

0.76 (0.26,2.25)

1.81 (0.35,9.36)

1.44 (0.52,4.02)

1.66 (0.47,5.90)

0.73 (0.20,2.67)

1.53 (0.59,3.99)

3.88 (1.15,13.12)

0.78 (0.23,2.68)

1.82 (0.59,5.55)

2.22 (0.95,5.15)

0.84 (0.30,2.40)

1.57 (0.58,4.27)

1.29 (0.38,4.38)

1.31 (0.44,3.89)

ERT

2.37 (0.43,13.24)

1.90 (0.61,5.93)

2.18 (0.56,8.52)

0.96 (0.24,3.85)

0.65 (0.14,3.09)

1.63 (0.29,9.28)

0.33 (0.06,1.89)

0.77 (0.14,4.07)

0.93 (0.21,4.17)

0.36 (0.07,1.80)

0.66 (0.13,3.26)

0.54 (0.09,3.09)

0.55 (0.11,2.87)

0.42 (0.08,2.35)

DC

0.80 (0.15,4.30)

0.92 (0.15,5.79)

0.40 (0.06,2.60)

0.81 (0.33,1.96)

2.04 (0.64,6.56)

0.41 (0.13,1.34)

0.96 (0.33,2.79)

1.17 (0.54,2.51)

0.44 (0.17,1.19)

0.83 (0.32,2.12)

0.68 (0.21,2.19)

0.69 (0.25,1.93)

0.53 (0.17,1.65)

1.25 (0.23,6.72)

CIK

1.15 (0.31,4.28)

0.51 (0.13,1.94)

0.70 (0.22,2.24)

1.77 (0.44,7.09)

0.36 (0.09,1.45)

0.83 (0.23,3.06)

1.01 (0.35,2.95)

0.39 (0.11,1.33)

0.72 (0.22,2.39)

0.59 (0.15,2.36)

0.60 (0.17,2.14)

0.46 (0.12,1.79)

1.09 (0.17,6.84)

0.87 (0.23,3.24)

BCAA

0.44 (0.09,2.04)

1.60 (0.48,5.27)

4.04 (0.98,16.59)

0.81 (0.20,3.38)

1.89 (0.50,7.17)

2.31 (0.77,6.97)

0.88 (0.25,3.13)

1.64 (0.48,5.62)

1.34 (0.32,5.53)

1.37 (0.37,5.02)

1.04 (0.26,4.18)

2.47 (0.38,15.91)

1.98 (0.52,7.58)

2.28 (0.49,10.59)

AIT

  1. ERT External radiotherapy, BCAA Branched-chain amino acids, IRT Internal radiotherapy, HAIC Hepatic artery infusion chemotherapy, DC Dendritic cell, CIK Cytokine-induced killer, AIT Adoptive immunotherapy, IFN Interferon, OCT Oral chemotherapy, TACE Transcatheter arterial chemoembolization, PVC Portal vein chemotherapy, SOR Sorafenib, NA Non-adjuvant